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ABSTRACT
Background: Sodium-glucose co-transporter-2
(SGLT2) inhibitors (gliflozins) are the newest
class of medication available to treat type 2
diabetes (T2DM). Recent findings from the first
complete cardiovascular safety trial in SGLT2
inhibitors, the Empagliflozin, Cardiovascular
Outcomes, and Mortality in type 2 diabetes
(EMPA-REG OUTCOMES) trial, demonstrated
reduced cardiovascular outcomes in people with
high cardiovascular risk. How to apply these
findings to clinical practice remains unclear,
with questions remaining on who will reap this
cardiovascular benefit.
Aim: To describe the proportion of people in
the real world currently treated with SGLT2
inhibitors who meet the inclusion criteria of the
EMPA-REG trial and therefore could expect the
cardiovascular benefit identified by the trial.
Similarly, to describe the proportion of people
from the whole T2DM population who could
also expect this same benefit.
Design and Setting: Routinely collected data
from UK primary care in the Royal College of
General Practitioners (RCGP) Research and
Surveillance Centre (RSC) database will be used.
The study population will include all people
with T2DM within this database (approximately
60,000). We will perform a cross-sectional
investigation to describe the characteristics of
people currently using SGTL2 inhibitors com-
pared with the population of the EMPA-REG
trail. We will similarly compare the character-
istics of the RCGP RSC T2DM cohort with the
inclusion criteria of the EMPA-REG trial.
Method: People with T2DM using a pre-existing
verified clinical ontological process will be
identified, as will people with prescriptions for
SGLT2 inhibitors and other medications using
Read coded and other proprietary coding sys-
tems. Descriptive statistics will be used to
characterise the key clinical characteristics of
people with T2DM using SGLT2 inhibitors and
to compare these characteristics to people
included in EMPA-REG trial; the proportion of
people who match the trial criteria will be
reported.
Planned Outputs: Peer review publication
reporting the real world lessons for clinical
practice.
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
2587F0603F89AAF4.
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INTRODUCTION
Sodium glucose co-transporter 2 (SGLT2) inhi-
bitors, also known as gliflozins, are a new class
of oral medication for the treatment of hyper-
glycaemia in type 2 diabetes (T2DM). They
improve glycaemic control through the inhibi-
tion of glucose reuptake by SGLT2 in the prox-
imal tubule of the kidney [1, 2]. This action is
independent of insulin secretion and activity
and, therefore, these agents are not considered
to predispose to hypoglycaemia [3]; they also
promote modest, but sustained, weight loss [4].
Inhibition of SGLT2 also promotes urinary
sodium loss [5, 6] which, along with weight
reduction, may be responsible for the early
blood pressure-lowering effects observed in tri-
als [7]. The reduction in weight and blood
pressure seen in clinical trials are likely to be
clinically meaningful and are potentially useful
additional benefits of these agents.
Three SGLT2 inhibitors are available in both
Europe and the USA, namely, canagliflozin, dapa-
gliflozin and empagliflozin. SGLT2 inhibitors have
been found to provide excellent glycaemic
improvement in randomised controlled trials
when used as a single agent [8] and when used in
combination with metformin [3, 4, 9], sulfony-
lureas [10, 11] or insulin [12, 13]. However, clinical
trials areperformedonselectedpatientgroupsand,
therefore, the trial results may not be fully repli-
cated in ‘real world’ clinical practice. In this con-
text, The Association of British Clinical
Diabetologists nationwide exenatide audit
demonstrated a differing real world efficacy profile
to that reported by clinical trials [14]. Whilst early
data with dapagliflozin (the first drug available in
the SGLT2 inhibitor class) has demonstrated good
efficacy in the real world [15] additional analyses
on a larger scale are still needed.
Recent findings from the first cardiovascular
safety trial in SGLT2 inhibitors to be completed,
the BI 10773 (Empagliflozin) Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus
Patients (EMPA-REG OUTCOME) trial demon-
strated reduced cardiovascular outcomes in
people with high cardiovascular risk (Table 1)
who were treated with empagliflozin [16]. How
these findings can be extrapolated into real
world clinical practice remains unclear. Other
cardiovascular safety trials are still ongoing and
will help to answer some of these questions as
their inclusion criteria are somewhat broader
than those of the EMPA-REG trial, with a lower
cardiovascular risk population included. In the
meantime, a comparison of the characteristics of
people treated with SGLT2 inhibitors in clinical
practice with those of the EMPA-REG trial is
important to enable an understanding of how
these important trial results can be applied to
clinical practice. A measure of the proportion of
people with T2DM, to whom these trial criteria
apply in clinical practice, is vitally important to
enable correct interpretation of the results.
AIM AND METHODS
The study will be a cross-sectional analysis of all
people with T2DM included in the Royal Col-
lege of General Practitioners Research (RCGP)
and Surveillance Centre (RSC) database to
identify people initiated on SGLT2 inhibitors
and to describe their cardiovascular risk profile.
The proportion of people who have a similar
cardiovascular risk profile to those included in
the EMPA-REG trial will also be reported.
OBJECTIVES
The aim of this study will be to compare the
clinical characteristics of people initiated on
SGLT2 inhibitors with those of people included
in the EMPA-REG OUTCOMES trial.
Primary Objectives
1. To identify how many people initiated on
an SGLT2 inhibitor in clinical practice meet
the inclusion criteria for the EMP-REG trial.
2. To provide a breakdown of this proportion
by:
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(a) the number of people with each inclu-
sion criteria for EMPA-REG,
(b) by duration of diabetes,
(c) by number of concurrent diabetes
agents and presence or absence of
insulin use.
3. To describe the clinical characteristics (age,
gender distribution, weight, blood pressure,
renal function and time since diagnosis) of
people in the each of the above groups.
Secondary Objectives
4. To also identify how many people initiated
on each SGLT2 inhibitor separately (cana-
gliflozin, dapagliflozin, and empagliflozin)
meet the inclusion criteria for the
EMPA-REG trial, comparing each SGLT2
inhibitor as a subgroup analysis—providing
sufficient numbers are available.
5. To identify how many people in clinical
practice, in the entire cohort, meet the
inclusion criteria for the EMP-REG trial.
6. To provide a breakdown of this proportion
by:
(a) the number of people with each inclu-
sion criteria for EMPA-REG,
(b) by duration of diabetes,
(c) by number of concurrent diabetes
agents and presence or absence of
insulin use.
7. To describe the clinical characteristics (age,
gender distribution, weight, blood pressure,
Table 1 A summary of the major cardiovascular safety trials in sodium glucose co-transporter 2 inhibitors
Medication Cardiovascular
safety trial
Trial characteristics Trial outcomes
Canagliﬂozin CANVAS [27] vs. placebo (n = 4330)
Inclusion criteria: age C50 years, high
CV risk or age C30 years, with
previous MI
Follow-up: up to 7 years
Primary outcome: time to composite
of CV death, nonfatal MI or
ischaemic stroke
Study completion: February 2017
Dapagliﬂozin DECLARE-TIMI
58 [28]
vs. placebo (n = 17,276)
Inclusion criteria: age C40 years, high
CV risk
Follow-up: up to 6 years
Primary outcome: time to composite
of CV death, MI or ischaemic stroke
Study completion: April 2019
Empagliﬂozin EMPA-REG
OUTCOME
[16]
vs. placebo (n = 7034)
Inclusion criteria: age C18 years, very
high CV risk
Follow-up: 3.1 years
Primary outcome: time to composite
of CV death, nonfatal MI or stroke
Reduction in the primary outcome compared
with placebo (HR 0.86; 95% CI 0.74–0.99;
P = 0.04)
Reduced hospitalisation for heart failure (HR
0.65; 95% CI 0.57–0.82; P\0.001)
CV cardiovascular, CI conﬁdence interval, HR hazard ratio, MI myocardial infarction
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renal function and time since diagnosis) of
people in the each of the above groups.
DATA SOURCE
Routinely collected English general practice
data will be used to perform the study. These
data are suitable for this type of analysis for
several reasons [17]. Firstly, English general
practice is a registration-based system—people
have to register with a single general practi-
tioner (GP), and all individuals have a unique
national patient identifier, namely, the
National Health Service (NHS) number, which
facilitates linking data on patient movement
from one general practice to another as well as
deaths. This number makes the population
denominator reliable and valid. The NHS
number also helps facilitate data linkage,
pathology results for example, to the correct
record. Secondly, many GPs computerised in
the 1990s, with most prescribing being carried
out using computerised records. Coding of
chronic disease data and laboratory links
become nearly universal from around 2004.
Although not widely used internationally, the
UK uses the Read code system, an extensive
coding system which allows the detailed coding
of diagnosis, symptoms, signs, investigations,
therapy and health service management [18].
Diabetes data are particularly well recorded,
although care is needed to accurately find cases
and to differentiate between the different ways
data are recorded on the different computerised
medical record systems used by GPs [19, 20].
Sufficient details on prescription data are avail-
able to facilitate the study of the use and per-
sistence of medicine in real world therapy [21].
The RCGP RSC database includes the pri-
mary care records from 128 primary care prac-
tices distributed across England (1.7% of all
practices) and provides a broadly representative
population sample [22]. All included data are
recorded using the Read code 5-byte version 2
coding hierarchy. The coded data include
comprehensive diagnosis and treatment infor-
mation, prescriptions and laboratory data.
Inclusion of data recording UK primary care
pay-for-performance targets have led to a high
level of data completeness in these records,
particularly in the population of people with
T2DM [23].
We will use data from all the included pri-
mary care practices collated after January 1,
2016 and will include all patients with a diag-
nosis of T2DM who are older than 18 years on
or before this date. In those with T2DM we will
identify all those people initiated on SGLT2
inhibitors (canagliflozin, dapagliflozin, or
empagliflozin) at any time before January 1,
2016. For those with T2DM and a prescription
for SGLT2 inhibitor we will report their clinical
characteristics and the proportion of people
with a cardiovascular risk similar to that of the
EMPA-REG trial population.
DATA ANALYSIS
Our aim is to define and make explicit our
approach to using real world data to create real
world evidence [24, 25]. To this end, we use a
two-stage informatics ontology-based process to
identify people with T2DM [21]. This is a con-
cept-based approach to case and outcome iden-
tification [26]. In brief, the two stages are the
identification of all peoplewith diabetes (stage 1)
and then categorisation by diabetes type (stage
2). People with diabetes are identified using one
or more of the following: (1) a diabetes diagnosis
code, (2) glucose and glycated hemoglobin
(HbA1c) test results (two ormore consistent with
diabetes) or (3) the use of diabetes therapies (ex-
cluding metformin). People are classified by dia-
betes type based on their medication usage
history, diabetes type-specific diagnosis codes
and other key clinical characteristics (these
include age at diagnosis, duration of oral medi-
cation use, and body mass index at diagnosis).
The high cardiovascular risk inclusion crite-
ria for the EMPA-REG study are given in Table 2.
We will identify people with each of these car-
diovascular risk factors using our ontological
process to identify the nearest matching clinical
diagnostic codes, or other codes which identi-
fied the presence of the risk factor. We will
include the full description of this process and
the final list of codes generated in the final
manuscript.
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Table 2 A comparison of the inclusion criteria of the EMPA-REG OUTCOMES trial with the nearest match available
from routine UK primary care data
EMPA-REG OUTCOMES trial inclusion criteria Nearest match using routinely collected
primary care data
History of myocardial infarction
History of myocardial infarction[2 months prior to
informed consent
Coding of a myocardial infarction or other deﬁnite indicator
of a myocardial infarction
Coronary artery disease
Evidence of multi-vessel coronary artery disease, i.e. in C2
major coronary arteries or the left main coronary artery,
documented by any of the following:
Presence of signiﬁcant stenosis: C50% luminal narrowing
during angiography (coronary or multi-slice computed
tomography)
Previous revascularisation (percutaneous transluminal
coronary angioplasty ± stent or coronary artery bypass
graft[2 months prior to consent
The combination of revascularisation in one major
coronary artery and signiﬁcant stenosis (C50% luminal
narrowing) in another major coronary artery
Evidence of single-vessel coronary artery disease, C50%
luminal narrowing during angiography (coronary or
multi-slice computed tomography) not subsequently
successfully re-vascularised, with at least 1 of the following:
A positive non-invasive stress test for ischaemia
Hospital discharge for unstable angina B12 months prior
to consent
Evidence of coronary artery disease documented by any of
the following:
Coding of double coronary artery disease
Previous revascularisation (percutaneous transluminal
coronary angioplasty ± stent or coronary artery bypass
graft) of the coronary arteries
NB. Coding of the precise percutaneous intervention
performed in primary care is limited. Usually only a high
level code is included to indicate the procedure has been
undertaken. This coronary artery disease code search is
therefore likely to slightly overestimate the number of
people who meet the trial criteria
Unstable angina
Unstable angina[2 months prior to consent with evidence
of single- or multi-vessel coronary artery disease
Coding of unstable angina or code which indicates poor
angina control
History of stroke
History of stroke (ischaemic or haemorrhagic)[2 months
prior to consent
Coding of stroke (ischemic or haemorrhagic)
Diabetes Ther
STATISTICAL METHODS
Standard descriptive statistics (mean, standard
deviations etc.) will be used to describe the
characteristics of the various populations. This
will include describing baseline HbA1c at initi-
ation of therapy with SGLT2 inhibitor. We will
report the crude rates of each outcome measure
for each cohort, as well as the proportion of
people with each outcome of interest together
with 95% confidence intervals.
STRENGTHS AND LIMITATIONS
The strengths of the dataset have been broadly
eluded to in the ‘‘Data Source’’ section. The
large-scale ([1.2 million records) of this very
complete real world evidence dataset is a par-
ticular strength. Despite the large size of the
dataset only a minor of people with T2DM have
been initiated on SGLT2 inhibitors to date and
therefore subgroup analyses may not have suf-
ficient power to resolve differences between
groups.
An additional limitation is the potential for
missing data on EMPA-REG inclusion criteria in
the primary care record. A number of patients
may have the condition of interest without
documentation of this in the primary care
record. However, as all the EMPA-REG inclusion
criteria are major cardiovascular risk factors and
the monitoring and recording of these risk fac-
tors are part of current primary care pay for
performance targets in the UK (Quality and
Outcome Framework), this effect is likely to be
small. Any additional limitations identified
during the conduct of the study will be dis-
cussed in the final study manuscript.
COMPLIANCE WITH ETHICS
GUIDELINES
All data to be used have been anonymised at the
point of data extraction. No clinically identifi-
able information will be made available to
researchers or in any publications. The study
has been tested against the Health Research
Authority (HRA)/Medical Research Council
(MRC) ‘‘is this research’’ tool (http://www.hra-
decisiontools.org.uk/research/) and is consid-
ered to be an audit of current practice when
compared to best available evidence. The study
Table 2 continued
EMPA-REG OUTCOMES trial inclusion criteria Nearest match using routinely collected
primary care data
Peripheral artery disease
Occlusive peripheral artery disease documented by any of the
following:
Limb angioplasty, stenting or bypass surgery
Limb or foot amputation due to circulatory insufﬁciency
Evidence of signiﬁcant peripheral artery stenosis ([50% on
angiography, or[50% or haemodynamically signiﬁcant
via non-invasive methods) in 1 limb
Ankle brachial index\0.9 in C1 ankle
Coding of peripheral artery disease documented by any
of the following:
Limb angioplasty, stenting or bypass surgery
Limb or foot amputation
Coding of peripheral arterial disease of the lower
limb(s) including claudication, and peripheral
gangrene
A recorded ankle brachial index\0.9
EMPA-REG OUTCOMES BI 10773 (Empagliﬂozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus
Patients
Where speciﬁc disease information is not available from routine data (either due to coding limitations or due to limitations
in non-speciﬁc data entry) we have used broader criteria, for example, percentage luminal narrowing is rarely recorded in
primary care; we therefore include all people with coded coronary artery stenosis
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therefore does not require specific ethical
approval. Approval for this work has been
granted by the RCGP RSC study approval
committee.
CONCLUSION
This real world evidence cross-sectional analysis
will demonstrate which proportion of people
with T2DM, in an unselected population, are
likely to benefit from the cardiovascular pro-
tection demonstrated in the EMPA-REG trial.
These data will provide clinicians with valuable
insights into the best applications for these
important trial data.
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